Just guessing but would think a big part of the testing is not only the visual but what the blood work shows too. Side effects need to be determined over a period of time. Also, need to see how long it would take for symptoms to return to determine if multiple dosing or if a drug that needs to be taken on a regular basis to keep the skin effects from returning. Lots of questions to confirm. Is this the new top line status replacing existing medications? Makes sense especially if oral versus IV. It seems the company knows it works but need the time to secure the data for the partner who would then join them to complete the testing and final FDA approval process.

We all know the company knows well before they mention anything. They mention 'speaking with companies that have shown interest in P' is past obviously tense. Would assume these companies want to see the blood work and short and long term side effects, blood work, etc. before they make an offer. Nice to have a selection of interested parties vs. few or one.

Looks good from what we know so far. Interesting how the manipulators continue to dominate the pps. When the law suit is dismissed in March, B p3 go ahead soon, K data and p2 trial protocols being announced, it would seem April should be a time for people to give up their 0.10 shaving, buy to hold and let it rise. Ashcroft is banking on their options over 1.70 and would imagine they are happy to take the shares as part of their full services compensation. Now if they could find Mako and bring him/them out of the dark and even into a jail cell......